The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The plenary session at the ASCO 2022 annual meeting saw that rarest of things at a scientific conference: a standing ovation. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
George W. Sledge Jr., MD
Professor of Medicine, Stanford University School of Medicine
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM. 
Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment. 
In Brief

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

Lonny Yarmus was appointed head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center. A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.
Clinical Roundup

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed. 
Byline
George W. Sledge Jr., MD
Professor of Medicine, Stanford University School of Medicine
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account